Cervical cancer systemic inflammation score: a novel predictor of prognosis

Oncotarget. 2016 Mar 22;7(12):15230-42. doi: 10.18632/oncotarget.7378.

Abstract

Inflammation contributes to development and progression in a variety of cancers, including cervical cancer. We developed a novel cervical cancer systemic inflammation score (CCSIS) based on the preoperative platelet-to-lymphocyte ratio (PLR) and serum albumin levels. A retrospective analysis of clinical data from 795 patients with operable cervical cancer was then conducted to investigate the prognostic value of CCSIS and its association with the patients' clinicopathological features, overall survival (OS), and disease-free survival (DFS). CCSIS was predictive of OS and DFS. High CCSIS was correlated with more advanced FIGO stages, poor tumor differentiation, and the presence of PLN and LVSI. Both albumin levels and the PLR were independent prognostic indicators for operable cervical cancer. The use of the CCSIS could improve risk stratification and traditional clinicopathological analysis in cervical cancer.

Keywords: albumin; cervical cancer; disease free survival; overall survival; platelet to lymphocyte ratio.

MeSH terms

  • Biomarkers, Tumor / blood*
  • Female
  • Follow-Up Studies
  • Humans
  • Inflammation / pathology*
  • Lymphocytes / pathology*
  • Middle Aged
  • Neutrophils / pathology*
  • Prognosis
  • Retrospective Studies
  • Survival Rate
  • Uterine Cervical Neoplasms / blood*
  • Uterine Cervical Neoplasms / pathology*

Substances

  • Biomarkers, Tumor